No profile data available.
Palisade Bio, Inc. (PALI) is a healthcare company in the digestive system treatment drugs industry, based in Denver, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2024, down 100.0% from fiscal year 2023, and net income of -$14.44 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $268.38 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Palisade Bio reported $0 in revenue for fiscal year 2024, down 100.0% from $250,000 in fiscal year 2023. In Q3 2025 revenue was $0.
$268.38 million as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Abivax Société Anonyme (ABVX), Ironwood Pharmaceuticals, Inc. (IRWD), Phathom Pharmaceuticals, Inc. (PHAT), Cumberland Pharmaceuticals Inc. (CPIX).